Mimetas US Inc.
Gaithersburg, MD Part of BHI Management Inc.
- UEI
- QGP7JLTGMAK9
- CAGE
- 757F3
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, BHI Management Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
-
- 325320 Pesticide and Other Agricultural Chemical Manufacturing
- 325411 Medicinal and Botanical Manufacturing
- 325412 Pharmaceutical Preparation Manufacturing
- 325413 In-Vitro Diagnostic Substance Manufacturing
- 325414 Biological Product (except Diagnostic) Manufacturing
- 541380 Testing Laboratories and Services
- 541614 Process, Physical Distribution, and Logistics Consulting Services
- 541690 Other Scientific and Technical Consulting Services
- Corporate family
-
-
Parent
Rockville, MD
XUDKKZPGFMR6
-
Parent
Rockville, MD
XUDKKZPGFMR6
- SAM.gov registration date
- Physical address
- 704 Quince Orchard Rd #260, Gaithersburg, MD 20878, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Contract awards
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Biopico Systems Inc. | Irvine, CA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Plurexa LLC | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Xylyx Bio, Inc. | NY | — |
| Hesperos, Inc. | Orlando, FL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Lena Biosciences, Inc. | Atlanta, GA | — |
About the company
Mimetas US Inc. is a self-certified small disadvantaged business and for-profit organization based in Montgomery Village, Maryland. It provides advanced 3D cell culture and organ-on-a-chip technologies, including high-throughput screening platforms for disease modeling and drug discovery applications.
Through federal contracts, Mimetas US Inc. has received funding from agencies like the National Institutes of Health (NIH) and the National Cancer Institute. One notable award is a $2 million Small Business Innovation Research (SBIR) Phase II contract from NIH's National Cancer Institute for developing a 3D perfusable platform for high-throughput screening across diverse racial/ethnic cancer specimens. This contract aimed to create a system for evaluating cancer treatments on patient-derived tumor samples, enabling personalized medicine approaches.
Mimetas US Inc. has also received several federal grants, primarily from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A substantial $3.5 million project grant supports the development of the NephroPlate, a high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies. This project involves modeling various glomerular diseases, such as Alport syndrome, membranous nephropathy, diabetic nephropathy, and APOL1 nephropathy, to study disease mechanisms and screen potential treatments. Another $236,779 grant from NIDDK funded the initial phase of the NephroPlate project. These grants highlight Mimetas US Inc.'s expertise in developing advanced 3D cell culture models and organ-on-a-chip systems for disease modeling and drug discovery applications, with a focus on kidney diseases.
Quick answers
Is Mimetas US Inc. registered in SAM.gov?
Yes. Mimetas US Inc.'s SAM.gov registration is active through November 18, 2026.
Which contract vehicles does Mimetas US Inc. hold?
Mimetas US Inc. holds a place on 1 federal contract vehicle: Pre-Clinical Models of Infectious Diseases.
How does Mimetas US Inc. rank among federal contractors?
Mimetas US Inc.'s parent company, BHI Management Inc., ranked #18 in PSC B544 and #59 in NAICS 5611 in FY2025.
What is Mimetas US Inc.'s most recent federal award?
Mimetas US Inc.'s most recent federal grant award is Development of the nephroplate: a high-throughput kidney-on-a-chip platform for identifying chronic kidney disease… (R44DK127659), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 28, 2020.
On GovTribe
See Mimetas US Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors